ET1402L1-CAR

Drug Profile

ET1402L1-CAR

Alternative Names: AFP-CAR; alpha-fetoprotein-chimeric antigen receptor

Latest Information Update: 16 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eureka Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hepatocellular carcinoma

Highest Development Phases

  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 14 Jun 2017 ET1402L1-CAR is available for licensing as of 14 Jun 2017. https://www.eurekatherapeutics.com/partnerships/
  • 07 Jun 2017 Preclinical trials in Hepatocellular carcinoma in USA (Parenteral)
  • 07 Jun 2017 Eureka Therapeutics and City of Hope plans a phase I trial for Hepatocellular carcinoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top